Peter M. Castleman - 27 Feb 2025 Form 4 Insider Report for Caris Life Sciences, Inc.

Reporting relationship: Director
Issuer ticker: CAI on Nasdaq
Reported as of: 27 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2025, 18:31:04 UTC
Next SEC filing: 17 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ J. Russel Denton, Attorney-in-Fact

Key filing fact

Peter M. Castleman filed Form 4 for Caris Life Sciences, Inc. on 23 Jun 2025.

Key facts

This page summarizes Peter M. Castleman's Form 4 filing for Caris Life Sciences, Inc..
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jun 2025, 18:31.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001239594 Primary reporting owner

CASTLEMAN PETER M

Relationship: Director
Address: C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature: /s/ J. Russel Denton, Attorney-in-Fact
Signature date: 23 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAI transaction

Common Stock

Award

Transaction value: $0
Shares: +16,129
Change %
Price: $0.000000
Shares after: 16,129
Date: 27 Feb 2025
Ownership: Direct
Footnotes: F1

CAI transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +10,245,906
Change %: +40984%
Price: $0.000000
Shares after: 10,270,906
Date: 20 Jun 2025
Ownership: By CLS-PF-SPE, LLC
Footnotes: F2, F3

CAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 100,000
Date: 27 Feb 2025
Ownership: By Family Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CAI transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +2,500
Change %
Price: $0.000000
Shares after: 2,500
Date: 27 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500
Exercise price: $18.60
Footnotes: F4

CAI transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -40,983,607
Change %: -100%
Price
Shares after: 0
Date: 20 Jun 2025
Ownership: By CLS-PF-SPE, LLC
Underlying class: Common Stock
Underlying amount: 10,245,906
Exercise price: $0.000000
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. These restricted stock units were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.

Footnote F2

Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock.

Footnote F3

CLS-PF-SPE Manager, LLC is the manager of CLS-PF-SPE, LLC. Mr. Castleman is a manager of CLS-PF-SPE Manager, LLC and in such capacity has voting and investment power with respect to the shares held by CLS-PF-SPE, LLC. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Footnote F4

The stock option is fully vested and exercisable. These securities were previously reported on the Reporting Person's Form 3.